Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pyramid Labs Appoints Dirk Lange as CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Pyramid Labs Appoints Dirk Lange as CEO

Medhat Gorgy, who founded Pyramid in 1988, will continue to support the business as the Company’s chairman.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Pyramid Labs Inc., a CDMO with expertise in proteins, oligos and peptides, has appointed Dirk Lange as Chief Executive Officer.
 
Medhat Gorgy, who founded Pyramid in 1988 and has led the Company’s growth and evolution over its 36-year history, will continue to support the business as the Company’s chairman.
 
“I am excited to lead Pyramid during this pivotal time in the Company’s growth trajectory and as the company is doubling its commercial fill-finish capacity,” noted Lange. “It’s a critical time for clients to secure their drug product supply chain and we are building on a 36-year track record defined by quality, reliability and innovation. Pyramid’s relentless focus on integrity and performance created outstanding service levels and enabled dozens of clients to realize their vision and bring products into the clinic and to the market.”

Experience

Lange brings a wealth of knowledge and expertise in building and leading global teams in the CDMO sector and providing best-in-class services to their client bases. Lange most recently led MilliporeSigma’s Life Science Services business and previously was the CEO of KBI Biopharma and Selexis. He joins Pyramid at a point of accelerated growth, as the company is doubling its commercial fill-finish capacity.
 
“We are seeing increased demand for our DP development and manufacturing services across biologics, small molecules and specifically novel modalities such as oligo nucleotides, where Pyramid offers differentiated capabilities and years of experience,” Lange added.
 
“We are very pleased to welcome Dirk to the Pyramid team as we continue in our transformative growth phase,” commented Medhat Gorgy. “Pyramid will benefit from his vast experience in the pharmaceutical industry and depth of knowledge in this sector, and I look forward to supporting him in my new role as Chairman.”
 
Since Audax Private Equity’s investment in 2023, Pyramid has invested substantially in expanding its capacity to better service its clients, including a facility expansion to double vial-filling and syringe filling capacity.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics